Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
368
resultados
Última actualización
02/11/2026 [10:35:00]
Resumen de: US20260337666A1
The present invention provides methods of profiling gene and protein expression of a plurality of nuclei from a single cell type and comparing the profiles to determine variability among cell populations, samples from different subjects, and cells expressing a disease phenotype.
Resumen de: US20260335261A1
Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.
Resumen de: US20260337275A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: US20260338803A1
A method of detecting, predicting or monitoring the progress of amyloid angiopathy, ARIA (amyloid-related imaging abnormalities) or CAA (cerebral amyloid angiopathy) in an individual. The method comprises the step of: determining the presence or quantity of an Aβ protein fragment in a biological sample obtained from the individual, wherein the Aβ protein fragment is an Aβ1-40 or Aβx-34 fragment or a fragment of Aβ1-40.
Resumen de: US20260338802A1
The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.
Resumen de: AU2026253892A1
Abstract Compositions and kits for diagnosing and prognosing Alzheimer’s Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis- related molecules. Further compositions and kits employ panels of fluorophore- conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis- promoting agents and scavenger receptor agonists also appear. ct b s t r a c t c t
Resumen de: AU2026249053A1
A method for detecting p217+tau in blood-based samples from a subject with high 5 sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The 10 amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the 15 assay. ct c t
Resumen de: US20260337565A1
The present disclosure relates in some aspects to methods, cells, and compositions for preparing isolated engineered immune cells comprising T cell receptors (TCRs) capable of recognizing a disease-associated antigen. In some aspects, the immune cells are T cells for use in immunotherapy. Provided In an embodiment are T cell preparation methods, including isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are the isolated engineered T cells and compositions produced by the methods in the present disclosure. In some aspects, the methods prepare T cells for adoptive therapy. In an embodiment, the disease-associated antigen is a cancer-associated antigen.
Resumen de: US20260337258A1
Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.
Resumen de: US20260335295A1
A compound represented by Formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof according to one aspect can be utilized as a preventive or therapeutic agent and the like for degenerative diseases, such as macular degeneration (AMD), cerebral amyloid angiopathy, hereditary stroke (CADASIL), and Alzheimer's disease (AD), in which HTRA1 activity deficiency is a factor in the aggravation of the diseases, and can be utilized as an adjuvant for efficiently and accurately performing screening of an HTRA activity modulator without temperature changes or the addition of substrates.
Resumen de: US20260337661A1
The present disclosure provides compositions and methods useful in modulating integrated stress response (ISR) and associated diseases or disorders and methods of identifying ISR modulators. The present disclosure also provides methods of treating neurodegenerative conditions and predicting beneficial effects and identifying suitable targets for treatment.
Resumen de: AU2026249014A1
A method of processing a biological sample in a microfluidic cartridge by generating a target analyte, binding the analyte to magnetic particles, actuating a plunger mechanism to pressurise reagent pouches and dispense reagents into interconnected reagent wells and a primary fluidic conduit to establish a fluidic circuit, and sequentially magnetically transporting the analyte-bound magnetic particles through the fluidic circuit from one reagent well to the next for assay processing. On-chip burst pouch106 Empty reaction chamber Rocker Cam 102 Filled reaction chamber Cam 102 Filled reaction chamber ct c t i l l e d r e a c t i o n c h a m b e r
Resumen de: US20260338764A1
The present invention relates to a method of profiling the energetic metabolism of a single cells. The inventors designed a method that rapidly and efficiently measures the protein synthesis level in single cells upon inhibition of the different energy producing pathways. The method developed by the inventors permits to acquire energetic metabolism profiles with single cell resolution in non-abundant cells ex-vivo and permits to decrease to a minimum manipulation time, incubations and cost of sample preparation. The method is particularly suitable for determining activation state of a cell, diagnosing inflammatory diseases, or predicting the response of a subject to immunotherapy treatment. In particular, the present invention relates to a method of profiling the energetic metabolism in single cells comprising measuring the protein synthesis level of the cells and contacting the cell with different inhibitors of metabolic pathways.
Resumen de: US20260338774A1
0000 Disclosed herein are methods of detecting citrullinated polypeptides and/or citrullinated peptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in various body fluids and/or tissues of individuals with autoimmune diseases, for example the synovium of subjects with rheumatoid arthritis. Further disclosed are methods of diagnosing, treating, selecting an individual for treatment of, and monitoring the treatment of autoimmune diseases, such as rheumatoid arthritis or hidradenitis suppurativa. Kits for use with the methods described herein are also provided.
Resumen de: US20260335402A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: WO2026226519A1
Disclosed are methods of assessing apolipoprotein ("APOE") genotype based on multiple parallel assays. The assays allow for comparison of relative amounts of ApoE isoforms in patient samples to quickly determine relative isoform values without need of reference to calibrators. The methods further allow for diagnosis and/or risk assessment of a subject's likelihood of developing a neurodegenerative disease, such as Alzheimer's disease or suffering Amyloid-Related Imaging Abnormalities (ARIA) as a function of treatment for a neurodegenerative disease.
Resumen de: US20260338755A1
Rapid and accurate detection of personal exposure to or contamination with OP pesticides is critical to both research and clinical care for victims. However, this detection remains highly variable across commercially available assays, e.g., the Ellman method, and such assays may also not adequately detect low but clinically relevant levels of exposure biomarkers. Moreover, these assays are generally performed in the centralized laboratories, and is slow and expensive. These deficits translate into missed opportunities for the timely initiation of the most appropriate treatment and interventions for acutely or chronically poisoned victims. A simple, rapid, non-or minimally invasive biomonitoring tool for onsite sensitive and accurate detection of personal exposure to or contamination with OP pesticides is provided.
Resumen de: US20260338793A1
0000 A method for treating sarcopenia. The method involves measuring a protein or mRNA level of asporin, PADI2, adenosine 5′-monophosphoramidase HINT2, or HSDL2 in a biological sample isolated from a subject. The subject is diagnosed as having sarcopenia by comparing the protein or mRNA level of the subject measured with that of a control group, where the subject is diagnosed with sarcopenia when the protein or mRNA level of asporin or PADI2 in the subject is increased compared to that of the control group, or when the protein or mRNA level of adenosine 5′-monophosphoramidase HINT2 or HSDL2 in the subject is decreased compared to that of the control group. The subject diagnosed with sarcopenia is then treated.
Resumen de: EP4830807A2
0001 Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: WO2025137532A1
Disclosed herein are methods of measuring amyloid β protofibril levels in biological samples. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: EP4830718A2
0001 Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: AU2015269198A1
This application describes a compound represented by Formula (I): (I)
Resumen de: WO2025210040A1
The present invention provides a cell model to study Tau protein related diseases.
Nº publicación: JP2026535745A 27/10/2026
Solicitante:
エフ．ホフマン－ラロシュアーゲー
Resumen de: WO2025068363A1
The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.
BOPI
Sede Electrónica
